Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer

Yoshiyuki Tokuda, Nagio Takigawa, Toshiyuki Kozuki, Haruhito Kamei, Akihiro Bessho, Atsuhiko Tada, Katsuyuki Hotta, Kuniaki Katsui, Susumu Kanazawa, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31%. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.

Original languageEnglish
Pages (from-to)537-540
Number of pages4
JournalActa Oncologica
Volume51
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Radiotherapy
Thorax
Pneumonia
Radiation
Gallbladder Neoplasms
Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. / Tokuda, Yoshiyuki; Takigawa, Nagio; Kozuki, Toshiyuki; Kamei, Haruhito; Bessho, Akihiro; Tada, Atsuhiko; Hotta, Katsuyuki; Katsui, Kuniaki; Kanazawa, Susumu; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Acta Oncologica, Vol. 51, No. 4, 04.2012, p. 537-540.

Research output: Contribution to journalArticle

Tokuda, Yoshiyuki ; Takigawa, Nagio ; Kozuki, Toshiyuki ; Kamei, Haruhito ; Bessho, Akihiro ; Tada, Atsuhiko ; Hotta, Katsuyuki ; Katsui, Kuniaki ; Kanazawa, Susumu ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. In: Acta Oncologica. 2012 ; Vol. 51, No. 4. pp. 537-540.
@article{6449e79aaeb64156b650dff1ed10cea0,
title = "Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer",
abstract = "Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31{\%}. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.",
author = "Yoshiyuki Tokuda and Nagio Takigawa and Toshiyuki Kozuki and Haruhito Kamei and Akihiro Bessho and Atsuhiko Tada and Katsuyuki Hotta and Kuniaki Katsui and Susumu Kanazawa and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2012",
month = "4",
doi = "10.3109/0284186X.2011.631580",
language = "English",
volume = "51",
pages = "537--540",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer

AU - Tokuda, Yoshiyuki

AU - Takigawa, Nagio

AU - Kozuki, Toshiyuki

AU - Kamei, Haruhito

AU - Bessho, Akihiro

AU - Tada, Atsuhiko

AU - Hotta, Katsuyuki

AU - Katsui, Kuniaki

AU - Kanazawa, Susumu

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2012/4

Y1 - 2012/4

N2 - Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31%. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.

AB - Background. Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC), but clinical outcomes beyond five years are rarely reported. The aim of the present study was to identify the long-term results of a phase II study of docetaxel and cisplatin with concurrent thoracic radiation. Methods. We previously reported short-term outcomes from the phase II study, which enrolled 42 patients (aged ≤ 75 years) with unresectable stage III NSCLC. We continued to follow these patients for long-term clinical outcomes. Results. At a median follow-up for all patients of 6.3 years (range: 5.27.1 years), the median survival time was 2.1 years and the actual five-year survival rate was 31%. Among 14 patients who were progression-free longer than two years, three patients died due to bacterial or fungal pneumonia and one died due to gall bladder cancer. Conclusions. Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. Progression-free patients might be cautiously followed up taking precautions against emerging pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=84859773469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859773469&partnerID=8YFLogxK

U2 - 10.3109/0284186X.2011.631580

DO - 10.3109/0284186X.2011.631580

M3 - Article

VL - 51

SP - 537

EP - 540

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 4

ER -